에 대한 최신 뉴스 iShares MSCI China A ETF (BATS:CNYA)

iShares MSCI China A ETF

Financial Services

Technology

Industrials

Consumer Defensive

Basic Materials

Consumer Cyclical

Healthcare

Utilities

Energy

Communication Services

Real Estate

The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index. The index is designed to measure the equity market performance in the Peoples Republic of China, as represented by A-shares that are accessible through the Shanghai-Hong Kong Stock Connect program or the Shenzhen-Hong Kong Stock Connect program.

Kweichow Moutai Co., Ltd.

Ping An Financials

Some Concerns Linger

Asia

Large Cap

Emerging Market ETFs

Global

Econ #s

Tech

ETFs

ASHR

BABA

CNYA

CQQQ

CXSE

KWEB

MCHI

PowerShares Golden Dragon Halter USX China Portfolio

TCEHY

최근 몇 주 동안 중국 주식이 부양 정책에 힘입어 급격한 반등을 보였다. iShares MSCI China ETF(NYSE:MCHI)가 추적하는 MSCI China Index는 9월 24일부터 10월 7일 사이에 35% 이상 급등했다.

&#39;빠르고 격렬한 랠리&#39;가 올해 중국 주식을 S&amp;P 500 수익 대비 두 배 상승의 견인

Ray Dalio may no longer be steering the investment ship at Bridgewater Associates, but his recent warning on X has left little doubt about <a href="https://www.benzinga.com/topic/ray-dalio">where he thinks</a> the world is headed. 
"We're witnessing a classic breakdown of the major monetary, political, and geopolitical orders," Dalio wrote, calling it a "once in a lifetime" phenomenon, the kind that "has happened many times in history, when similarly unsustainable conditions were in place."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">At the moment, a huge amount of attention is rightly being paid to the newly announced tariffs and their significant impacts on markets and economies. But very little attention is being paid to the circumstances that caused them—and to the even bigger disruptions likely still… <a href="https://t.co/wPIgzDscbk">https://t.co/wPIgzDscbk</a>
&mdash; Ray Dalio (@RayDalio) <a href="https://twitter.com/RayDalio/status/1909296359955460347?ref_src=twsrc%5Etfw">April 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The spark? Tariffs. But the fire, Dalio says, runs deeper.
&#8220;These tariff announcements are important developments. But most people are overlooking the much larger forces that are driving just about everything," Dalio said.
While he's not actively managing the fund, Bridgewater's latest 13F filing offers a glimpse into how the firm is positioning itself in the face of this macro upheaval.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44707736/expert-warns-of-perfect-storm-as-trump-tariffs-slam-global-stock-markets-advises-investors-to-seek-safety-in-gold-and-fixed-income-instruments">Expert Warns Of &#8216;Perfect Storm&#8217; As Trump Tariffs Slam Global Stock Markets — Advises Investors To Seek Safety In Gold And Fixed-Income Instruments</a>
<h2 class="wp-block-heading">Tariffs, Turmoil And A Bet On The Index</h2>
Despite Dalio's big-picture warning, Bridgewater's top holding as of the fourth quarter of 2024 was the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—now a whopping 22.1% of the portfolio. Add iShares Core S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and iShares Emerging Markets (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEMG#NYSE">IEMG</a>) and nearly half the firm's equity book is riding broad indices.
That's a defensive play wrapped in passive exposure, especially as markets wobble under new trade war concerns.
The fund didn't stop there. Among its top new buys were AT&amp;T Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), eBay Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) and PayPal Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) &#8211; low-multiple names that look like classic recession hedges.
Applovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) also made the list, a curious pick that may reflect a contrarian bet on adtech amid volatility.
<h2 class="wp-block-heading">From Tech Titans To Utility Muscle</h2>
Bridgewater has trimmed back tech allocations to the sector, which fell from 19.8% to 16.3% quarter over quarter. Still, it holds heavyweights like Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), albeit at lower portfolio weights than before.
Meanwhile, two quiet climbers in the portfolio are worth noting: Constellation Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) and Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>), both utility players sitting comfortably in the top 10 holdings. In a world Dalio sees veering toward chaos, old-school stability may be back in fashion.
<h2 class="wp-block-heading">Macro Chaos, Micro Calculations</h2>
Dalio's post paints a stark picture of structural breakdown—"unsustainable conditions" colliding with a new era of tariffs and geopolitical chess. While Bridgewater's allocations don't scream panic, the tilt toward broad ETFs, dividend-value names and utilities suggests the firm is bracing for bumps ahead.
Whether or not the VUCA (Volatile, Uncertain, Complex, Ambiguous) world Dalio describes becomes a reality, Bridgewater seems to be preparing for the long game &#8211; passive on the surface but deeply macro-aware under the hood.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/44705344/ray-dalio-says-dont-make-the-mistake-of-thinking-whats-happening-now-is-due-to-trump-tariffs">Ray Dalio Says Don&#8217;t Make The Mistake Of Thinking What&#8217;s Happening Now Is Due To Trump Tariffs</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Macro Economic Events

Broad U.S. Equity ETFs

Economics

Trading Ideas

EBAY

GOOG

GOOGL

IEMG

MSFT

NVDA

PYPL

Here's Where Bridgewater Is Placing Its Bets As Ray Dalio Warns Of 'Once-In-A-Lifetime' Breakdown

General

BTTR

Better Choice Company Regains Compliance With NYSE American Continued Listing Standards

Mizuho analyst Nitin Kumar maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Neutral and lowers the price target from $140 to $132.

News

Price Target

Analyst Ratings

Mizuho Maintains Neutral on Phillips 66, Lowers Price Target to $132

Wells Fargo analyst Timur Braziler upgrades Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) from Equal-Weight to Overweight and lowers the price target from $110 to $100.

Upgrades

BPOP

Wells Fargo Upgrades Popular to Overweight, Lowers Price Target to $100

<a href="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3Q700W:0-fed-s-kashkari-neither-rate-hike-nor-cut-is-off-the-table-hurdle-is-high-for-both/" title="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3Q700W:0-fed-s-kashkari-neither-rate-hike-nor-cut-is-off-the-table-hurdle-is-high-for-both/">https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3Q700W:0-fed-s-kashkari-neither-rate-hike-nor-cut-is-off-the-table-hurdle-is-high-for-both/</a>

Federal Reserve

Fed's Kashkari Says First Priority Must Be Keeping Long-run Inflation Expectations Anchored;  Announced Tariffs Much Higher, Broader Than Expected, Resulting In Larger Economic Effect And Shock To Confidence; Near-term Inflation Will Climb, Purchasing Power Will Go Down, Investment Will Likely Be Lower, GDP Will Be Smaller Due To Tariffs; Once Confident On Inflation Expectations, Could Then Focus On Trade-offs Between Goals

Needham analyst Mike Matson reiterates InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) from Hold to Hold.

Reiteration

INMD

Needham Reiterates Hold on InModeto Hold

Wells Fargo analyst Elyse Greenspan downgrades WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) from Overweight to Equal-Weight and lowers the price target from $70 to $69.

Downgrades

Wells Fargo Downgrades WR Berkley to Equal-Weight, Lowers Price Target to $69

Fed's Kashkari Says No Monetary Policy Response, Up Or Down, Should Be Off The Table; Hurdle To Changing Policy Rate Has Increased Due To Tariffs; Bar Is Higher For Cutting Rates Even If Economy, Labor Market Weakens; Falling Neutral Rate Due To Tariffs Reduces Immediate Need For Rate Hike; Risk Of Unanchoring Inflation Expectations Seems To Have Increased Notably; 'Too Risky' To Look Through Inflation Effects Of Tariffs

In response to ongoing market uncertainty, PacBio is executing a plan to reduce both headcount across all functions and non-headcount related expenses to lower its annualized non-GAAP operating expense run-rate by $45 million to $50 million by year end in relation to its prior guidance of $270 million to $280 million. Following the reductions, PacBio aims to focus on its highest-impact long-read platform development initiatives.&nbsp;

Management

PACB

PacBio Says In Response To Ongoing Market Uncertainty, PacBio Is Executing A Plan To Reduce Both Headcount Across All Functions And Non-Headcount Related Expenses To Lower Its Annualized Non-GAAP Operating Expense Run-Rate By $45M-$50M

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">180.66</td>
<td align="right">0.93</td>
<td align="right">0.51</td>
<td>193.6K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">36.29</td>
<td align="right">-0.79</td>
<td align="right">-2.14</td>
<td>16.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">130.47</td>
<td align="right">-2.51</td>
<td align="right">-1.89</td>
<td>54.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">75.40</td>
<td align="right">-1.04</td>
<td align="right">-1.37</td>
<td>485.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">84.97</td>
<td align="right">-1.16</td>
<td align="right">-1.35</td>
<td>16.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">73.58</td>
<td align="right">-0.69</td>
<td align="right">-0.93</td>
<td>39.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">72.52</td>
<td align="right">-0.57</td>
<td align="right">-0.78</td>
<td>50.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">75.88</td>
<td align="right">-0.47</td>
<td align="right">-0.62</td>
<td>26.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">43.65</td>
<td align="right">-0.27</td>
<td align="right">-0.62</td>
<td>795.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">115.76</td>
<td align="right">-0.66</td>
<td align="right">-0.57</td>
<td>139.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">175.42</td>
<td align="right">-0.92</td>
<td align="right">-0.53</td>
<td>27.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For April 9, 2025

Mizuho analyst Nitin Kumar maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Outperform and lowers the price target from $49 to $46.

Mizuho Maintains Outperform on Devon Energy, Lowers Price Target to $46

Guidance

PacBio Sees Prelim. Q1 Revenue $36.9M, Reiterates 2025 Revenue Guidance

Needham analyst Mike Matson reiterates Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and maintains $116 price target.

MMSI

Needham Reiterates Buy on Merit Medical Systems, Maintains $116 Price Target

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09065053/Microvast-0409-01-900x600-1.png" alt="" class="wp-image-10063" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09065053/Microvast-0409-01-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09065053/Microvast-0409-01-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09065053/Microvast-0409-01-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The EV battery maker reported a huge increase in its gross profit margin last year, a significant achievement that can help it stand out in a crowded field
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Microvast's gross profit margin jumped to 31.5% in 2024 from 18.7% the prior year, already exceeding the company's target for this year</li>
<li>The U.S.-based EV battery maker is reducing its reliance on China by boosting its sales to other markets, which is also helping to beef up its margins</li>
</ul>
Turbocharged margins are driving electric-vehicle (EV) battery maker&nbsp;Microvast Holdings Inc.&nbsp;(MVST.US) ahead at full speed on its journey to profitability.
The company's revenue increased about 8% year-on-year in the fourth quarter to $113.4 million, according to its&nbsp;<a href="https://www.globenewswire.com/news-release/2025/03/31/3052829/0/en/Microvast-Reports-2024-Financial-Results.html">latest earnings disclosure</a>&nbsp;last week. That kind of top-line growth isn't going to awe anyone, even though its revenue for the quarter was a record. For all 2024, Microvast's revenue grew by a more respectable 24% to $379.8 million, also a record.
What's more remarkable is a drastic improvement in Microvast's gross profit margin, which jumped to 36.6% in last year's fourth quarter from 22% a year earlier. That paralleled its performance for the entire year, when the figure jumped to 31.5% from 18.7%, surpassing its goal of hitting 30% this year. The big margin improvements led to an 80% year-on-year surge in Microvast's gross profit for the fourth quarter and a 52% rise for 2024.
Microvast is based in the U.S. state of Texas but has strong ties to China – something it is apparently trying to downplay, which looks prudent as U.S.-China trade tensions continue to rise. Its founder is a Chinese American, and China is the biggest customer for its batteries. The company also manufactures its products in China, though it wants to shift some production to a U.S. facility in the state of Tennessee if and when it raises necessary funding. It has a plant in Germany as well.
Margins can go up and down all the time, but the large improvement Microvast is reporting isn't something you see everyday. The company only provided a general explanation for the increase, with CFO Feriel Khambabi crediting improved operational efficiency, increased utilization and cost control on the company's earnings call.
Although the company didn't specially mention it, diversification away from China probably also played a role in the big margin improvement, as other markets overtook China to account for a majority of the company's revenue last year. Prices in Western markets for comparable products are typically higher than in China, helping a company to boost margins.
Improving margins is critical for Microvast because it operates in an extremely crowded industry where the top 10 global manufacturers, led by China's&nbsp;CATL&nbsp;(300750.SZ) and&nbsp;BYD&nbsp;(1211.HK; 002594.SZ), control nearly 90% of the market. Microvast is among the many smaller companies fighting for the remaining 10%. The company has been around for nearly two decades, showing that longevity doesn't necessarily spell big success in the fast-moving EV battery market.&nbsp;
To stand out, Microvast positions itself as an innovator focused on a niche of the market providing batteries for large vehicles. In its latest annual report for 2024, the company says its mission is to "innovate lithium-ion battery designs without relying on past technologies."
"We call this true innovation," Microvast declares in the report. "We started without preconceived notions of lithium-ion battery creation, unlike many companies that repurposed legacy technologies for new markets like electric vehicles – a process we consider product development rather than true innovation. To understand this difference is to understand what we have set out to achieve."
<h4 class="wp-block-heading">Geographic diversification</h4>
Microvast specializes in high-performance batteries for large vehicles like trucks, buses and trains. It says a key strength of its products is that they charge quickly and have longevity that eliminates the need for battery replacements during the lifecycle of a vehicle.
The company is American but also has close China connections, including its founding by Chinese American entrepreneur Wu Yang in Stafford, Texas in 2006. China is also the company's single biggest market, which isn't surprising given the country is the world's largest EV market.
But Microvast's sales elsewhere are growing, reducing its reliance on China – a step that looks especially important in the current environment of ever-increasing U.S.-China trade tensions. China accounted for more than 51% of Microvast's revenue as recently as 2023, but the figure dropped sharply to 33% last year as Europe, the Middle East and Africa (EMEA) zoomed to become its largest market accounting for about half of sales. U.S. sales also quadrupled, albeit from a small base, to reach 4%.
Heavy reliance on one country or region for sales is never good, especially if that market is China, where competition among battery makers is fierce and a prolonged economic slowdown is depressing vehicle sales. Increasing sales in the West looks prudent not only for diversification purposes, but also because sales to such markets typically carry higher margins.
Microvast may be a small player in the EV battery market, but at least in terms of margins, it beat some of its larger rivals last year. Its 31.5% gross margin for 2024 easily exceeded 24% for CATL and 19% for BYD, although the latter isn't directly comparable as it also makes cars.
While its margins may be enviable, Microvast still lags the larger companies on its bottom line. The company is losing money, and its net loss widened last year. One key factor was an impairment loss of $93 million following a decision to pause construction of the Tennessee plant due to insufficient funding. The company also recorded a large expense related to a convertible loan from its founder.
But these extraordinary factors aside, Microvast generated positive cash flow from its operations last year, something it hasn't been able to do for years. Investors clearly focused on such positives, sending Microvast shares rallying more than 50% in three days after the latest earnings release.
Microvast shares are still down more than 80% from where they traded in July 2021 when the company went public through a merger with a special purpose acquisition company (SPAC). They trade at a price-to-sales ratio of 1.8, far below 2.7 for industry leader CATL.
As a manufacturer, Microvast can obviously beef up its profit margins only so much. But if it can maintain its current level of operational profitability, it may well be able to become profitable on a net basis – something the lone analyst who follows the company on Yahoo Finance expects to happen this year. There will undoubtedly be headwinds, including Donald Trump's latest tariff bombs, which will make U.S.-China trade more costly. That could pressure Microvast's strong margins, though an ability to defend its profitability in such challenging times could also help to shore up its stock price.

Equities

Travel

Opinion

Markets

Microvast Reduces Dependence On China; Gross Margin Soars For 2024

Needham analyst Mike Matson reiterates OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Buy and maintains $42 price target.

KIDS

Needham Reiterates Buy on OrthoPediatrics, Maintains $42 Price Target

Wells Fargo analyst Timur Braziler upgrades Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) from Equal-Weight to Overweight and lowers the price target from $27 to $26.

Wells Fargo Upgrades Associated Banc to Overweight, Lowers Price Target to $26

Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) with a Buy and maintains $30 price target.

BCYC

Needham Reiterates Buy on Bicycle Therapeutics, Maintains $30 Price Target

WIIM

MULN

Mullen Automotive shares are trading lower after the company announced a 1-for-100 reverse stock split.

IMS is One of the Largest Independent Multi-Specialty Practices in the State
Arizona Represents 15th State in National Primary Care-Centric Care Delivery Network
ARLINGTON, Va., April 09, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) announced it has signed a definitive agreement to enter Arizona in partnership with Integrated Medical Services, Inc. (IMS), one of the largest independent multi-specialty practices in the state, with approximately 70 physicians and advanced practice providers caring for patients in 21 locations. The group manages over 28,000 attributed lives in a variety of value-based care arrangements across Commercial, Medicare, Medicare Advantage and Medicaid.
With this transaction, Privia Health launches Privia Medical Group—Arizona, providing a compelling new alternative for independent providers across the state to care for all patients regardless of the reimbursement model. IMS will serve as the anchor practice with a long-term management agreement with Privia Health and continue to be physician-owned and operated.
IMS is expected to be implemented on the Privia Platform in the fourth quarter of 2025. The transaction and launch in Arizona is expected to be profitable starting in the fourth quarter of 2025 and for full-year 2026. Financial terms and additional details were not disclosed.
"We are extremely pleased to partner with IMS, one of the largest independent practices in Arizona, as we expand Privia's national presence," said Jason Ross, EVP, Medical Groups, Privia Health. "The demographics of the Arizona market offer a compelling value-based care opportunity. We look forward to building on the IMS providers' culture of delivering high quality care in the community as we continue to execute our strategy of aligning with like-minded providers and practices to offer high quality care to patients across the U.S."

Contracts

PRVA

Privia Health Group Signs Definitive Agreement To Enter Arizona In Partnership With Integrated Medical Services. Group Manages Over 28,000 Attributed Lives

Needham analyst David Saxon reiterates ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) from Hold to Hold.

ZIMV

Needham Reiterates Hold on ZimVieto Hold

최근 몇 주 동안 중국 주식이 부양 정책에 힘입어 급격한 반등을 보였다. iShares MSCI China ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NYSE">MCHI</a>)가 추적하는 MSCI China Index는 9월 24일부터 10월 7일 사이에 35% 이상 급등했다.
뱅크 오브 아메리카의 애널리스트 위니 우(Winnie Wu)와 윌리 찬(Willie Chan)이 설명한 바와 같이, 이 &#8220;빠르고 격렬한&#8221; 랠리는 전 세계 다른 주요 시장의 성과를 초과했으며, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)로 추적되는 S&amp;P 500 지수의 연초 대비 상승 폭의 두 배 이상에 달했다.
이 랠리는 중국 당국이 발표한 일련의 공격적인 통화 완화 정책과 정부의 불안정한 부동산 시장 안정화에 대한 재확약으로 촉발되었다.
<h2 class="wp-block-heading">연초 대비 성과: MSCI 차이나, S&amp;P 500 두 배 상승</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-583894" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07123344/image-41-1024x455.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07123344/image-41-1024x455.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07123344/image-41-300x133.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07123344/image-41-768x342.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07123344/image-41-1536x683.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07123344/image-41.png 1920w" alt="" width="1024" height="455" /><figcaption class="wp-element-caption">차트:<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1"> Benzinga Pro</a></figcaption></figure>
<h2 class="wp-block-heading">2조 달러 규모의 시장 급등</h2>
9월 23일부터 30일까지 MSCI China Index는 거의 2조 달러의 시장 가치를 추가했다. 주요 수혜자는 귀주 마오타이(Kweichow Moutai)와 같은 블루칩 주식들이다. 귀주 마오타이는 39% 급등하여 880억 달러의 시가총액을 추가했으며, 텐센트 홀딩스 ADR(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>)은 15% 상승하여 700억 달러를 추가했다. 또한 알리바바 그룹 홀딩 – ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)는 27% 급등하여 580억 달러의 시가총액이 증가했다.
이러한 빠른 시장 상승은 투자자들 사이에서 중국 정책 당국이 경제적 도전 과제인 디플레이션 압박, 부동산 시장 침체 및 증가하는 지방 정부 부채 문제를 해결하기 위해 진지한 조치를 취하고 있다는 낙관론이 커지고 있음을 반영한다.
<h2 class="wp-block-heading">주요 부양 조치가 랠리를 촉발</h2>
이 랠리는 9월 23일부터 시작된 일련의 예상치 못한 정책 발표로 촉발되었다. 이날 중국 인민은행(PBoC)은 14일 역환매조건부채권 금리를 10bp(베이시스 포인트) 인하하여 1.85%로 조정하고, 약 106억 달러(745억 위안)를 은행 시스템에 주입하여 시장을 놀라게 했다.
다음 날, PBoC 총재인 판궁성(Pan Gongsheng)은 더 큰 조치를 발표했다. 중앙은행은 지급준비율을 50bp 인하하여 약 1,425억 달러(1조 위안)를 금융 시스템에 주입할 것이며, 7일물 환매조건부채권 금리를 20bp 인하하고, 기준 대출 우대 금리와 기존 모기지 금리를 약 50bp 인하하겠다고 약속하여, 가계 이자 지급액을 약 210억 달러(1,500억 위안) 줄일 수 있다고 밝혔다.
그 후 9월 25일에는 PBoC가 1년 만기 중기대출금리(MLF)를 30bp 인하하고, 국영은행에 자본을 주입하겠다는 재정적 약속을 발표했습니다.
마지막으로, PBoC는 상업은행에게 기존 모기지 금리를 대출 우대 금리보다 30bp 이상 낮추도록 지시했다. 이 조치는 10월 31일 이전에 시행되어야 한다.
<h2 class="wp-block-heading">중국 주식 ETF, 대규모 상승 기록</h2>
이러한 조치들은 중국 주식 ETF들이 S&amp;P 500 및 기타 글로벌 벤치마크를 상당히 초과하는 성과를 거두게 만들었다. 9월 24일부터 10월 7일 사이에 여러 중국 중심 ETF가 놀라운 상승률을 기록했다:
<ul>
<li>Invesco China Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQQQ#NYSE">CQQQ</a>): +52%</li>
<li>iShares MSCI China A ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNYA#NYSE">CNYA</a>): +48%</li>
<li>XTrackers Harvest CSI 300 China A-Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASHR#NYSE">ASHR</a>): +47%</li>
<li>WisdomTree China ex-State-Owned Enterprises Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXSE#NASDAQ">CXSE</a>): +43%</li>
<li>KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>): +40%</li>
<li>SPDR S&amp;P China ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXC#NYSE">GXC</a>): +38%</li>
<li>Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>): +36%</li>
<li>iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>): +32%</li>
</ul>
<h2 class="wp-block-heading">향후 주의사항: 조정 가능성</h2>
이번 랠리가 강력했지만, 뱅크 오브 아메리카의 애널리스트들은 주의가 필요하다고 조언했다.
애널리스트들은 &#8220;부동산 시장을 안정화하고 지방 정부 채무를 구조조정하기 위한 추가 재정적 자극과 과잉 생산/디플레이션 문제를 해결하기 위한 구조적 개혁이 필요하다&#8221;고 지적했다.
그들은 현재의 &#8220;모든 것을 사라&#8221; 단계가 긍정적인 촉매제가 더 이상 나타나지 않으면 곧 끝날 수 있다고 경고했다.
높은 베타를 가진 소비재, 부동산 및 중개 주식은 급격히 상승한 후 이익 실현의 첫 번째 대상이 될 수 있다. 그러나 애널리스트들은 장기 투자자들이 잠재적인 조정을 매수 기회로 볼 수 있다고 제안했다. 특히 대형 인터넷 주식과 고수익 국영기업(SOE) 섹터는 변동성이 적다고 평가했다.
2024년 4분기에 대해 뱅크 오브 아메리카는 인터넷(미디어, 온라인 소매), 보험 및 헬스케어(특히 생명 과학 및 생명공학) 섹터에 대해 긍정적인 전망을 유지하고 있다. 이들은 3분기 동안 강력한 성과를 보였다.
그들은 강력한 랠리 이후 중개 주식에 대해 신중하게 접근하고, 실적 하향 조정 및 매력적이지 않은 가치 평가로 인해 유틸리티(가스, 수도) 부문에 대해 하향 조정을 했다. 또한, 부동산, 자동차, 건축 자재 및 화학 부문에 대해서는 기본적인 회복이 더 오랜 시간이 걸릴 것이라고 믿고 부정적 입장을 유지하고 있다.

지금 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41208397/this-alibaba-analyst-turns-bullish-here-are-top-5-upgrades-for-monday">이 알리바바 애널리스트가 긍정적으로 전환했습니다. 월요일을 위한 상위 5개 업그레이드를 확인하세요</a></li>
</ul>
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

'빠르고 격렬한 랠리'가 올해 중국 주식을 S&P 500 수익 대비 두 배 상승의 견인

Comments

iShares MSCI China A ETF

뉴스

에 대한 최신 뉴스 iShares MSCI China A ETF (BATS:CNYA)

화요일, 10월 08, 2024

뉴스

파트너 / 기고자

벤징가 글로벌